Paclitaxel (Chemotherapy)

DRUG3 trials

Sponsors

Hoffmann-La Roche, HC Biopharma Inc., University of Texas Southwestern Medical Center

Conditions

Advanced Solid Tumor CancerOvarian CancerTriple-Negative Breast Cancer (TNBC)

Phase 1

A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer

RecruitingNCT07381829

HC Biopharma Inc.Advanced Solid Tumor Cancer

Start: 2025-10-27End: 2026-12-30Target: 328Updated: 2026-02-02

Phase 2

Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC

Not yet recruitingNCT07786428

University of Texas Southwestern Medical CenterTriple-Negative Breast Cancer (TNBC)

Start: 2026-10-01End: 2030-10-31Target: 60Updated: 2026-08-26

Phase 3

Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)

CompletedNCT01684878

Hoffmann-La RocheOvarian Cancer

Start: 2012-10-22End: 2016-04-28Updated: 2017-05-23

Related Papers

Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer.

2019-08-159 citations

Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial.

2016-06-013 citations

Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum-resistant ovarian cancer (PROC): AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomized phase III trial.

Journal of Clinical Oncology2015-05-206 citations

PENELOPE/AGO-OVAR 2.20: A double-blind placebo (PLA)-controlled randomized phase III ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinum-resistant ovarian cancer.

Journal of Clinical Oncology2014-05-204 citations

Pertuzumab (P) plus chemotherapy (CT) for platinum-resistant ovarian cancer: Safety run-in results of the PENELOPE trial.

Journal of Clinical Oncology2014-05-201 citations